Traditional Chinese medicine composition for tonifying kidney and activating blood

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for tonifying kidney and activating blood. Under the guidance of the theory of kidney deficiency and blood stasis, the invention provides a prescription with the efficacy of tonifying kidney and promoting blood circulation, the prescription is continuously optimized clinically, and the basic composition of the prescription for tonifying kidney and promoting blood circulation is finally provided and comprises raw astragalus membranaceus, schisandra chinensis, ligusticum wallichii, salvia miltiorrhiza, rheum officinale, charred rheum officinale, dandelion and patrinia. Compared with the prior art, the traditional Chinese medicine composition has better effects of delaying or controlling renal function deterioration and delaying renal fibrosis.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for invigorating the kidney and promoting blood circulation. Background Art

[0002] Chronic renal failure is a general term for the symptoms of various chronic kidney diseases that have developed to a certain degree. It is a progressive renal parenchymal injury that leads to renal atrophy and decreased glomerular filtration rate. It is characterized by accumulation of metabolites, water imbalance, electrolyte disorders, and involvement of other organs. The main pathological change of the kidney is renal fibrosis, and the degree of fibrosis is related to the condition.

[0003] The global burden of chronic renal failure is becoming increasingly severe, and its pathogenesis is complex. Its occurrence is closely related to factors such as age, gender, genes, underlying diseases, lifestyle and diet. Chronic renal failure is also characterized by low awareness, low intervention and low control rates. Its onset is insidious and its etiology is complex. Many patients are diagnosed clinically only after clinical symptoms appear or even after severe renal damage, thus missing the best time for early drug intervention.

[0004] Common clinical manifestations of chronic renal failure include nausea and vomiting, low back pain, fatigue, oliguria, edema, skin itching, anemia, etc., which often involve multiple organs and systems, which greatly increases the difficulty of disease prevention and treatment. Once patients enter end-stage renal disease, they can only undergo renal replacement therapy to maintain survival, which imposes a huge economic burden on individuals, families and society, and affects the quality of life of patients. Modern medicine generally believes that chronic renal failure is difficult to reverse. In the non-dialysis stage, the main intervention methods are to control or eliminate its progression factors and symptomatic treatment, and there is no specific drug.

[0005] Prior art CN 117243995 A discloses a Chinese medicine composition for treating chronic renal failure, and its preparation method and application, which can significantly improve the renal function indicators of patients with chronic renal failure and delay the progression of chronic kidney disease, but its therapeutic effect still needs to be further improved. Summary of the invention

[0006] Based on the above-mentioned prior art, the present invention readjusts and optimizes the Chinese medicine formula, and proposes a Chinese medicine composition for tonifying the kidney and activating blood circulation, comprising the following components in parts by weight: 30-70 parts of raw astragalus, 10-30 parts of schisandra chinensis, 10-30 parts of chuanxiong, 5-20 parts of salvia miltiorrhiza, 5-20 parts of rhubarb, 10-25 parts of rhubarb charcoal, 10-25 parts of dandelion, and 10-25 parts of patrinia herb.

[0007] The Chinese medicine composition for invigorating the kidney and activating blood circulation of the present invention starts from the root cause of kidney deficiency, can enhance the body's immune ability, improve microcirculation, achieve treatment of both the symptoms and the root causes, and pays attention to the foundation of the acquired and acquired constitutions, achieves treatment of the spleen and kidney at the same time, corrects the balance of yin and yang through a combination of multiple drugs, regulates water metabolism, and improves the patient's symptoms. This is the uniqueness of the prescription for invigorating the kidney and activating blood circulation of the present invention.

[0008] Among them, raw astragalus is the main medicine in the prescription. "Tangye Bencao" points out that it replenishes the kidney's vital energy and is an internal medicine, which is a medicine for the upper, middle, lower, internal and external triple burners.

[0009] Schisandra chinensis and rhubarb are the assistant drugs. Schisandra chinensis has five flavors: sour, sweet, pungent, bitter and salty. It enters the lung, heart and kidney meridians and has the effects of astringency, invigorating qi and promoting body fluid, tonifying kidney and calming the mind. Ligusticum chuanxiong and salvia miltiorrhiza can promote blood circulation, dissipate blood stasis and stop bleeding. Rhubarb is cold in nature and bitter in taste. It enters the spleen, stomach, large intestine, liver and pericardium meridians and has the effects of purging heat and relieving constipation, removing blood stasis and promoting menstruation, and removing dampness and detoxification.

[0010] Rhubarb charcoal, Chuanxiong, and Danshen are adjuvants. Rhubarb charcoal is warm in nature, light in taste, and flat in qi, which weakens its ability to cleanse the stomach and intestines, clear the bowels and purge, and takes its effect of promoting blood circulation and stopping bleeding, removing blood stasis and unblocking collaterals. The two are used together, which has the characteristics of clearing without hurting the stomach, descending without damaging the spleen, cooling without leaving blood stasis, and restraining without clinging to evil. Chuanxiong is pungent in taste and warm in nature. It enters the liver, gallbladder, and pericardium meridians, promotes blood circulation and qi, dispels wind and relieves pain. It is a blood-qi medicine and has the effect of unblocking blood and qi; Danshen is said to be "one Danshen has the same effect as four ingredients", which has the effect of promoting blood circulation and removing blood stasis, nourishing blood and blood, and removing blood stasis without hurting the body.

[0011] Toxic evil is also an important cause of the occurrence and development of chronic renal failure. Therefore, dandelion and Patrinia salsa are used together to achieve the effect of detoxification and dispersing nodules.

[0012] Preferably, the Chinese medicine composition comprises the following components in parts by weight: 30-62 parts of raw astragalus, 15-22 parts of schisandra chinensis, 15-22 parts of chuanxiong, 8-20 parts of salvia miltiorrhiza, 8-20 parts of rhubarb, 15-22 parts of rhubarb charcoal, 10-22 parts of dandelion, and 10-22 parts of patrinia herb.

[0013] Preferably, the Chinese medicine composition comprises the following components in parts by weight: 58-62 parts of raw astragalus, 18-22 parts of schisandra chinensis, 18-22 parts of chuanxiong, 8-12 parts of salvia miltiorrhiza, 8-12 parts of rhubarb, 18-22 parts of rhubarb charcoal, 18-22 parts of dandelion, and 18-22 parts of patrinia herb.

[0014] Preferably, the Chinese medicine composition comprises the following components in parts by weight: 60 parts of raw astragalus, 20 parts of schisandra chinensis, 20 parts of chuanxiong, 10 parts of salvia miltiorrhiza, 10 parts of rhubarb, 20 parts of rhubarb charcoal, 20 parts of dandelion, and 20 parts of patrinia herb.

[0015] Furthermore, the present invention provides a traditional Chinese medicine preparation, which is prepared using the traditional Chinese medicine composition as a raw material.

[0016] Preferably, the Chinese medicine preparation is a decoction, pill, powder, paste, pill, wine, tablet, granule, capsule, injection, aerosol, spray, gel, lozenge, syrup, mixture or lotion.

[0017] Preferably, the preparation method of the traditional Chinese medicine preparation comprises: taking the traditional Chinese medicine composition as raw material, mixing the raw material with water, soaking the mixture, and then decocting the mixture to obtain the traditional Chinese medicine preparation.

[0018] Preferably, the raw material and water are mixed in a mass volume ratio of (800-1000) g: (2-3) L.

[0019] Preferably, the decoction is divided into two times, the first decoction is 60 minutes, and the second decoction is 50 minutes. The decoctions after the two decoctions are mixed and concentrated to obtain the traditional Chinese medicine preparation.

[0020] Preferably, the soaking time is more than 30 minutes; and / or the decoction is performed in an automatic decoction machine at a pressure of 0.8-0.9 MPa.

[0021] Furthermore, the present invention provides the use of the traditional Chinese medicine preparation in the preparation of medicine for treating chronic renal failure.

[0022] Furthermore, the present invention provides the use of the traditional Chinese medicine preparation in the preparation of a drug for delaying renal fibrosis.

[0023] Compared with the prior art, the present invention has the following beneficial effects: The present invention is mainly aimed at chronic renal failure-renal failure stage CRF (also meets CKD stage 3-4, 15≤eGFR<45ml / (min.1.73m 2 )) patients, during this period, their renal function deteriorates rapidly, and it is a critical treatment period for entering end-stage renal disease. Patients are prone to refractory edema, massive proteinuria, gastrointestinal dysfunction, adverse cardiovascular events, metabolic disorders, etc., and show severe anxiety, depression, insomnia, and a decline in their quality of life.

[0024] Based on long-term clinical practice and scientific research, the present invention proposes a prescription with the effect of "tonifying the kidney and activating blood circulation" under the guidance of the theory of "kidney deficiency and blood stasis", and continuously optimizes it in clinical practice, and finally proposes the basic composition of the tonifying kidney and activating blood circulation prescription of the present invention. Compared with the prior art, the present invention has a better effect of delaying or controlling the deterioration of renal function and delaying the occurrence of renal fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the result of HE staining.

[0026] Figure 2 This is the result of Masson staining.

[0027] Figure 3 This is the result of collagen Ⅰ immunohistochemistry. DETAILED DESCRIPTION

[0028] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme in the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. The "parts" in the following embodiments represent parts by weight. If the specific techniques or conditions are not specified in the embodiments, they are all conventional methods or carried out according to the techniques or conditions described in the literature in this field, or according to the product manual. The reagents and instruments used, etc., which do not indicate the manufacturer, are all conventional products that can be purchased through regular channels.

[0029] Example 1 The present embodiment provides a Chinese medicine preparation, and the preparation method is as follows: weigh 60 parts of raw astragalus, 20 parts of schisandra chinensis, 20 parts of chuanxiong, 10 parts of salvia miltiorrhiza, 10 parts of rhubarb, 20 parts of rhubarb charcoal, 20 parts of dandelion, and 20 parts of patrinia herb, and mix them into Chinese medicine slices, then take 900g of the Chinese medicine slice mixture and mix it with 2.5L of water, soak for 30min, and then decoct twice in an automatic decoction machine at 0.85MPa, the first decoction is 60 minutes, and the second decoction is 50 minutes, the decoctions after the two decoctions are mixed and concentrated to prepare the Chinese medicine preparation.

[0030] Example 2 This embodiment provides a Chinese medicine preparation, and the preparation method is different from that of embodiment 1 only in that: Weigh 15 parts of raw astragalus, 10 parts of schisandra chinensis, 8 parts of chuanxiong, 8 parts of salvia miltiorrhiza, 8 parts of rhubarb, 8 parts of rhubarb charcoal, 5 parts of dandelion, and 5 parts of patrinia herb, and mix them to make Chinese herbal medicine slices.

[0031] Comparative Example This comparative example provides a Chinese medicine preparation, the preparation method of which is different from that of Example 1 only in that: Weigh 3 parts of Astragalus, 3.5 parts of Rhubarb Carbonized, 3.5 parts of Raw Rhubarb, 2 parts of Chuanxiong, 2 parts of Psoralea corylifolia, 15 parts of Taraxacum, 15 parts of Stir-fried Cassia Seed, 2 parts of Fructus Scutellariae, and 6 parts of Scutellaria barbata, and mix them into a Chinese herbal medicine slice (i.e., the formula disclosed in CN 117243995 A).

[0032] Test example In this test example, the pharmacodynamics of the Chinese medicine preparations prepared in the above examples and comparative examples were evaluated by animal experiments, and the steps were as follows: 1. Preparation of chronic renal failure mouse model: After 7 days of adaptive feeding, 6 6-week-old male C57BL / 6 mice were randomly selected as the blank control group (control). The remaining mice were given adenine to establish the model. 2.5 g of adenine was added to 100 ml of normal saline to make a suspension with a concentration of 2.5%. The concentration was 200 mg kg -1 ·d -1 The mice were given the drug by intragastric administration once a day, and the blank control group was given the same volume of normal saline. The modeling period was 28 days.

[0033] 2. Grouping and administration: The modeling mice were divided into a chronic renal failure (CRF) group, Example 1, Example 2 and a comparative group, with 6 mice in each group. The comparative group was gavaged once a day at 26.1 g / kg / d, and Example 1 and Example 2 were gavaged once a day at 23.4 g / kg / d and 11.7 g / kg / d, respectively. The blank control group and the CRF group were gavaged with an equal volume of double distilled water for 8 weeks.

[0034] 3. Sample collection: After 8 weeks of intragastric administration, the eyeballs of the mice were removed to collect systemic blood, which was centrifuged at 4°C to obtain the upper serum and stored at -80°C for creatinine and urea nitrogen detection. Creatinine and urea nitrogen were detected according to the instructions of Nanjing Jiancheng (C011-2-1) and Wanlei Biological (WLA120), respectively. The kidney tissue was removed and weighed, a part of it was fixed in 4% paraformaldehyde and used to make paraffin sections for HE staining, Masson staining and collagen I immunohistochemistry, and a part of the fresh tissue was directly stored at -80°C for extraction of kidney tissue protein and nucleic acid for molecular biology detection.

[0035] 4. The test method for Western Blot detection of fibrosis-related proteins FN and α-SMA expression is as follows: 1) Take an appropriate amount of fresh tissue or tissue frozen at -80 ℃, put it into a 2 ml centrifuge tube, add RIPA lysis buffer (about 500 μl of lysis buffer for every 100 mg of tissue), add grinding beads, homogenize the tissue using a high-throughput tissue grinder, and lyse on ice for 30 minutes.

[0036] 2) Place the lysed sample in a 4°C centrifuge and centrifuge at 12,000 rpm for 10 minutes. Transfer the supernatant to a new centrifuge tube.

[0037] 3) The protein concentration was determined using the Thermo Fisher BCA protein quantification kit.

[0038] (1) Standard dilution: Dilute the protein standard sample with distilled water to draw the protein standard curve.

[0039] (2) Sample dilution: Add 27 μl of distilled water to each new centrifuge tube and add 3 μl of the protein sample to be tested.

[0040] (3) Preparation of protein quantification working solution: Mix solution A and solution B in a ratio of 50:1 to prepare the corresponding volume of working solution.

[0041] (4) Result determination: Take a 96-well plate and add 10 μl of diluted standard or protein sample to each well, then add 200 μl of reaction working solution, avoiding the addition of bubbles. Incubate the 96-well plate at 37°C for 30 minutes. Measure the absorbance at 560 nm using an ELISA reader. Draw a standard curve and calculate the protein concentration.

[0042] 4) Adjust the protein volume according to the sample protein concentration, add 5 × SDS loading buffer and distilled water to make the concentration of each group of samples consistent. Heat in a 100-degree metal bath for 10 minutes and cool on ice.

[0043] 5) Protein electrophoresis: Prepare electrophoresis buffer (dilute 10×Running buffer to 1×Running buffer with distilled water), take out the sample comb. Use a pipette to add equal amounts of protein sample to the comb holes, and add protein molecular weight markers to the gel holes on both sides. Turn on the power supply, first use 80 volts for concentration, and adjust the voltage to 120 volts when the sample is electrophoresed to the lower separation gel.

[0044] 6) Transfer: Prepare transfer buffer (100 ml 10×Transfer buffer + 200 ml anhydrous methanol + 700 ml distilled water) in advance and place in a 4 ℃ refrigerator for precooling. Combined with the indicated position of bromophenol blue in the loading buffer and the degree of separation of protein molecular weight markers, stop electrophoresis when the separation near the target protein is observed. Take a PVDF membrane with a pore size of 0.45 μm and activate it in anhydrous methanol for about 15 seconds. Place the gel and PVDF membrane in the order of positive electrode surface-filter paper-PVDF membrane-strip-filter paper-negative electrode surface, remove the bubbles between the gel and PVDF membrane, place in the transfer rack, and pour the transfer buffer to completely cover the transfer device. Transfer at 100 volts for 2 hours on ice.

[0045] 7) Blocking: After the transfer, remove the PVDF membrane and discard the gel. Wash with TBST three times, 5 minutes each time, and wash off the transfer buffer. Prepare a milk blocking solution with a mass volume ratio of 5% with skim milk, and block at room temperature for 1 hour.

[0046] 8) Primary antibody incubation: Wash three times with TBST, 5 minutes each time, and wash off the milk blocking solution. Dilute the serum with TBST to prepare a 5% primary antibody diluent, and incubate the corresponding primary antibodies FN (proteintech, MA5-15613) and α-SMA (Wanlei Bio, WL02510) at 4°C overnight. Wash three times with TBST, 20 minutes each time.

[0047] 9) Secondary antibody incubation: Select the corresponding secondary antibody according to the source of the primary antibody, dilute the horseradish peroxidase-labeled secondary antibody (Zhongshan Jinqiao) with 5% milk, and incubate at room temperature for 1 hour. Wash three times with TBST, 10 minutes each time.

[0048] 10) Chemiluminescence: Prepare the chemiluminescent substrate in a 1:1 ratio according to the instructions of the Millipore chemiluminescent substrate. Prepare it before use and avoid light during use. Turn on the chemiluminescent imager, run the software, and cool the instrument to below -30 °C. Use filter paper to absorb the excess TBST on the PVDF membrane and evenly add the luminescent substrate.

[0049] 11) Statistical analysis: Grayscale values ​​were analyzed using ImageJ, and statistical analysis was performed using Prism.

[0050] 5. The test method for q-PCR detection of fibrosis-related mRNA expression is as follows: 1) Lysis: Take fresh tissue or tissue frozen at -80 ℃, put it into a 2 ml centrifuge tube, add 500 μl Trizol reagent, break it with a tissue homogenizer, and then lyse it on ice for 30 minutes. Pre-cool the centrifuge to 4 ℃.

[0051] 2) Separation: Add 100 μl of chloroform to each tube, shake vigorously for 15 seconds to mix, let stand at room temperature for 20 minutes, and centrifuge at 12,000 rpm at 4°C for 20 minutes.

[0052] 3) Precipitation: Transfer the supernatant to a new centrifuge tube. Add an equal volume of isopropanol and mix well. Let stand for 10 minutes and centrifuge at 12,000 rpm at 4°C for 20 minutes to fully precipitate the RNA.

[0053] 4) Washing: Discard the supernatant. A white precipitate is visible, which is RNA. Add 500 μl of pre-prepared 75% ethanol, mix well, and centrifuge at 8000 rpm at 4°C for 10 minutes. Discard the supernatant and dry at room temperature to allow the ethanol to evaporate completely. The white precipitate becomes transparent.

[0054] 5) Dissolution: Add appropriate amount of DEPC water to dissolve. Measure RNA concentration and purity by spectrophotometer.

[0055] 6) Reverse transcription: Use the first-strand cDNA synthesis kit of Yishen Biotechnology (11141ES) to reverse transcribe into cDNA using the extracted RNA as a template.

[0056] The reverse transcription system is shown in Table 1.

[0057] Table 1

[0058] Prepare the reaction system on ice, add the above components to the PCR tube in sequence, put the PCR tube into the PCR instrument, set the reaction conditions to incubate at 25℃ for 5 minutes, reverse transcribe at 55℃ for 15 minutes, react at 85℃ for 5 minutes, and cool at 4℃. Store in a -80℃ refrigerator.

[0059] 7) Real-time fluorescence quantitative PCR: Reagents used: Yisheng Biotechnology qPCR SYBR Green Master Mix (NoRox), (the Mix contains hot-start DNA polymerase, SYBR Green I fluorescent dye, dNTPs, Mg 2+ ), the reaction system is shown in Table 2.

[0060] Table 2

[0061] The amplification procedure is shown in Table 3.

[0062] Table 3

[0063] The reaction system was prepared on ice, and protection from light was taken during the experiment. Amplification was performed using the Roche Applied Science Lightcycler 96 instrument.

[0064] The primer sequences used for q-PCR are shown in Table 4.

[0065] Table 4

[0066] 6. Experimental results (1) Kidney weight The average kidney weight of mice in each group is shown in Table 5.

[0067] Table 5 Statistics of kidney weight of mice in each group x±s

[0068] Comparison of kidney weight showed that the kidneys of mice in the CRF model group were atrophied and their weight was reduced. After 8 weeks of administration, the kidney atrophy of the drug-treated group was alleviated compared with that of the model group. The formulation of Example 1 of the present invention had better therapeutic effect than that of Example 2 and the comparative example. There was no statistical difference in kidney weight between the comparative example and Example 2 of the present invention.

[0069] (2) Serum creatinine and urea nitrogen Table 6 Statistics of serum creatinine and urea nitrogen in each group of mice x±s

[0070] Comparison of serum creatinine and urea nitrogen levels showed that the biochemical indices of mice in the CRF model group were significantly increased ( P <0.0001), after 8 weeks of administration, the creatinine and urea nitrogen of the drug administration group decreased, and the prescription of Example 1 of the present invention was more effective than that of the comparative example ( P <0.05), there was no statistical difference in creatinine and urea nitrogen between the comparative example and Example 2 of the present invention.

[0071] (3) HE staining The results of HE staining are as follows Figure 1 As shown in the figure, the glomerular structure of mice in the control group was clear and complete, the tubular epithelial cells were arranged regularly, and there was no inflammatory cell infiltration in the renal interstitium; the pathological staining of the CRF model group showed inflammatory cell infiltration, glomerular sclerosis and atrophy, tubular dilatation, tubular epithelial cell vacuoles, degeneration, shedding, casts, and tubular interstitial fibrosis, which were alleviated to varying degrees in the drug-treated groups.

[0072] (4) Masson staining The results of Masson staining are as follows Figure 2 The statistics of Masson staining positive area of ​​kidney tissue of mice in each group are shown in Table 7.

[0073] Table 7 Statistics of Masson staining positive area of ​​kidney tissue of mice in each group x±s

[0074] Masson staining and statistics showed that the blue-stained area of ​​renal interstitial collagen fibers in the CRF model group increased ( P <0.0001); after 8 weeks of administration, the area of ​​renal interstitial fibrosis in the mice in the drug-treated group was reduced ( P <0.0001), and the formula of Example 1 of the present invention is more effective in inhibiting renal interstitial fibrosis than the formula of the comparative example and Example 2 ( P <0.01), there was no statistical difference in the positive area between the comparative example and Example 2 of the present invention.

[0075] (5) Collagen I immunohistochemistry The results of collagenⅠ immunohistochemistry were Figure 3 The statistics of the positive areas of collagenⅠ immunohistochemical staining in the kidney tissue of mice in each group are shown in Table 8.

[0076] Table 8 Statistics of positive areas of collagen Ⅰ immunohistochemical staining in kidney tissue of mice in each group x±s

[0077] Immunohistochemistry showed that a large number of brown positive areas appeared in the renal interstitium of the CRF model group, which was consistent with the results of Masson. The renal fibrosis of the CRF model mice was obvious; the brown area of ​​the drug-treated group decreased (P < 0.01), and the positive area of ​​Example 1 was less than that of the control group ( P <0.05), there was no statistical difference in the positive area between the comparative example and Example 2 of the present invention.

[0078] (6) Western Blot detection of fibrosis-related protein expression The results of Western Blot detection of the expression levels of fibrosis-related proteins FN and α-SMA are shown in Table 9.

[0079] Table 9 Relative quantitative statistics of FN and α-SMA in kidney tissue of mice in each group x±s

[0080] WB and statistics showed that the protein expression of FN and α-SMA related to fibrosis in the renal tissue of mice in the CRF model group was higher than that in the control group ( P <0.01), after 8 weeks of administration, the expression of FN protein in Example 1 was significantly decreased compared with that in Example 2 and the comparative example ( P <0.01), there was no statistical difference between Example 2 and the control group; the expression of α-SMA in Example 1 and 2 groups decreased compared with the CRF group ( P <0.05), the expression of α-SMA showed a decreasing trend after treatment in the control group, but there was no statistical difference.

[0081] (7) q-PCR detection of fibrosis-related mRNA expression The test results are shown in Table 10.

[0082] Table 10 Statistics of mRNA expression of FN and α-SMA in kidney tissue of mice in each group x±s

[0083] q-PCR results showed that the mRNA expression levels of FN and α-SMA in the renal tissues of mice in the CRF model group were significantly higher than those in the control group (P <0.0001), after 8 weeks of administration, the mRNA expression of fibrosis-related FN and α-SMA in the drug-treated group was lower than that in the CRF model group ( P <0.0001), wherein the fibrosis inhibition effect of Example 1 is better than that of the comparative example, and the mRNA levels of FN and α-SMA in Example 1 are lower ( P <0.01, P <0.05), there was no difference in the mRNA levels of FN and α-SMA between the comparative example and Example 2 of the present invention.

[0084] In summary, the pathogenesis of chronic renal failure is complicated, mostly mixed with deficiency and excess, among which deficiency of the body is the basis, excess of pathogenic factors is the deficiency, deficiency of the body's vital energy, and feeling of exogenous pathogenic factors, and the two affect each other; the lesion organs are mainly in the kidney, and the spleen and lungs are accumulated at the same time. The cause of the disease is mostly spleen and kidney failure, unfavorable gasification, dampness, turbidity and toxic evils are contained in the triple energizer, and finally lead to the occurrence and development of the disease. The kidney-tonifying and blood-activating prescription of the present invention tonifies the kidney and promotes blood circulation, and blood circulation strengthens the kidney, and is supplemented with dampness-removing and detoxification, and the two cooperate with each other to achieve the pathological changes of improving kidney deficiency and blood stasis, so that the body's yin and yang are balanced, and the evil is removed and the body is at peace. The present invention preliminarily confirms that the Chinese medicine composition of the present invention can effectively delay the progress of chronic renal failure through the comparison of animal experiments, and has better efficacy than the prior art.

[0085] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention comprises the following components in parts by weight: 30-70 parts of raw astragalus, 10-30 parts of schisandra chinensis, 10-30 parts of chuanxiong, 5-20 parts of salvia miltiorrhiza, 5-20 parts of rhubarb, 10-25 parts of rhubarb charcoal, 10-25 parts of dandelion and 10-25 parts of patrinia herb.

2. The Chinese medicine composition according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 30-62 parts of raw astragalus, 15-22 parts of schisandra chinensis, 15-22 parts of chuanxiong, 8-20 parts of salvia miltiorrhiza, 8-20 parts of rhubarb, 15-22 parts of rhubarb charcoal, 10-22 parts of dandelion and 10-22 parts of patrinia herb.

3. The Chinese medicine composition according to claim 2, characterized in that: The invention comprises the following components in parts by weight: 58-62 parts of raw astragalus, 18-22 parts of schisandra chinensis, 18-22 parts of chuanxiong, 8-12 parts of salvia miltiorrhiza, 8-12 parts of rhubarb, 18-22 parts of rhubarb charcoal, 18-22 parts of dandelion and 18-22 parts of patrinia herb.

4. A Chinese medicine preparation, characterized in that: The method is prepared using the Chinese medicine composition according to any one of claims 1 to 3 as raw material.

5. The Chinese medicine preparation according to claim 4, characterized in that: The Chinese medicine preparation is a decoction, pill, powder, paste, pill, wine, tablet, granule, capsule, injection, aerosol, spray, gel, lozenge, syrup, mixture or lotion.

6. The Chinese medicine preparation according to claim 4, characterized in that: The preparation method comprises: taking the Chinese medicine composition as raw material, mixing the raw material with water, soaking the mixture, and then decocting the mixture to obtain the Chinese medicine preparation.

7. The Chinese medicine preparation according to claim 6, characterized in that: The raw materials and water are mixed in a mass volume ratio of (800-1000) g: (2-3) L; and / or, the decoction is divided into two times, the first decoction is 60 minutes, and the second decoction is 50 minutes, and the decoctions after the two decoctions are mixed and concentrated to obtain the traditional Chinese medicine preparation.

8. The Chinese medicine preparation according to claim 6, characterized in that: The soaking time is more than 30 minutes; and / or the decoction is performed in an automatic decoction machine at a pressure of 0.8-0.9 MPa.

9. Use of the Chinese medicine preparation according to any one of claims 1 to 8 in the preparation of a medicament for treating chronic renal failure.

10. Use of the Chinese medicine preparation according to any one of claims 1 to 8 in the preparation of a drug for delaying renal fibrosis.

Images